Alignment Healthcare (NASDAQ:ALHC) President Sells $586,500.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 30,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $19.55, for a total value of $586,500.00. Following the completion of the sale, the president directly owned 947,313 shares of the company’s stock, valued at $18,519,969.15. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dawn Christine Maroney also recently made the following trade(s):

• On Friday, May 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $16.09, for a total value of $482,700.00.
• On Wednesday, April 15th, Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock. The shares were sold at an average price of $20.87, for a total value of $626,100.00.
• On Wednesday, March 18th, Dawn Christine Maroney sold 36,749 shares of Alignment Healthcare stock. The shares were sold at an average price of $17.84, for a total value of $655,602.16.

Alignment Healthcare Stock Up 0.2%

Shares of ALHC traded up $0.03 on Monday, reaching $19.78. The company’s stock had a trading volume of 4,684,470 shares, compared to its average volume of 5,900,816. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56. Alignment Healthcare, Inc. has a twelve month low of $11.63 and a twelve month high of $23.87. The stock has a market capitalization of $4.09 billion, a PE ratio of 219.78, a PEG ratio of 2.67 and a beta of 1.14. The firm has a fifty day moving average of $18.55 and a 200-day moving average of $19.42.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, April 30th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the business posted ($0.05) EPS. The firm’s revenue was up 33.3% compared to the same quarter last year. Equities analysts predict that Alignment Healthcare, Inc. will post 0.2 EPS for the current year.

Institutional Investors Weigh In On Alignment Healthcare

A number of institutional investors have recently added to or reduced their stakes in ALHC. Wellington Management Group LLP grew its position in Alignment Healthcare by 167.3% in the 3rd quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after purchasing an additional 6,940,277 shares in the last quarter. Bank of New York Mellon Corp grew its position in Alignment Healthcare by 232.5% in the 1st quarter. Bank of New York Mellon Corp now owns 3,313,110 shares of the company’s stock worth $58,377,000 after purchasing an additional 2,316,777 shares in the last quarter. Invesco Ltd. grew its position in Alignment Healthcare by 122.3% in the 2nd quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock worth $58,387,000 after purchasing an additional 2,294,739 shares in the last quarter. Capital World Investors bought a new stake in Alignment Healthcare in the 4th quarter worth about $44,203,000. Finally, Loomis Sayles & Co. L P bought a new stake in Alignment Healthcare in the 4th quarter worth about $44,162,000. 86.19% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ALHC shares. Raymond James Financial set a $22.00 target price on shares of Alignment Healthcare in a report on Thursday, May 7th. Barclays lowered their target price on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Wolfe Research started coverage on shares of Alignment Healthcare in a report on Friday, April 17th. They issued an “outperform” rating and a $24.00 target price on the stock. UBS Group upped their target price on shares of Alignment Healthcare from $21.00 to $22.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.30.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.